Obermeyer Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Obermeyer Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,500	Closed	-$270K	–	227
2023 Q1	$270K	Hold	30,500	–	–	0.02%	175
2022 Q4	$278K	Hold	30,500	–	–	0.02%	172
2022 Q3	$246K	Buy	+30,500	New	+$270K	0.02%	178
2015 Q3	–	Sell	-401,901	Closed	-$23.8M	–	127
2015 Q2	$23.8M	Sell	401,901 -2,425	-0.6%	-$150K	2.03%	17
2015 Q1	$25.2M	Sell	404,326 -1,110	-0.3%	-$64.5K	2.06%	13
2014 Q4	$23.3M	Buy	+405,436	New	+$22.6M	2.11%	11
2013 Q3	–	Sell	-1,051	Closed	-$41K	–	256
2013 Q2	$41K	Buy	+1,051	New	+$40.9K	0.01%	141

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Obermeyer Wealth Partners's TEVA Position: Q2 2023 in Review

Obermeyer Wealth Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 30,500 shares — an estimated $270K sold.

Obermeyer Wealth Partners first reported a position in TEVA in Q2 2013 and held it in 7 quarters. The position peaked at $25.2M in Q1 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

Obermeyer Wealth Partners reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Obermeyer Wealth Partners sold 30,500 Teva Pharmaceuticals shares in Q2 2023, an estimated $270K.
Obermeyer Wealth Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Obermeyer Wealth Partners's Teva Pharmaceuticals position peaked at $25.2M in Q1 2015.
428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Obermeyer Wealth Partners's 13F filing for Q2 2023, filed 7 Aug 2023.